echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > After 1 billion oral hypoglycemic drug Hausen, Sichuan pharmaceutical companies also entered the market

    After 1 billion oral hypoglycemic drug Hausen, Sichuan pharmaceutical companies also entered the market

    • Last Update: 2022-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 30, Sichuan State submitted a generic listing application for dapagliflozin tablets for pharmaceuticals


    Figure 1: The status of companies reporting for the production of dapagliflozin tablets recently

    Source: CDE official website

    Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).


    According to data from Meinnet.


    Figure 2: The market size of oral hypoglycemic drugs in the retail market

    Source: Mi Nei.


    Table 1: TOP5 oral hypoglycemic drugs in the retail market

    Source: Mi Nei.


    In Chinese urban physical pharmacies, the market size of oral hypoglycemic drugs is expected to remain above 5 billion yuan in 2021.


    AstraZeneca’s monopoly of the dapagliflozin market has ended.


    Source: CDE official website, Minet database

    Statistics are as of December 1.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.